Show simple item record
dc.description.abstractIn the May 2020 COVID-19 guidelines, we had stated that there were no specific therapeutic agents for COVID-19. We still do not have antivirals that can be given to prevent or treat COVID-19. However, a recent National Institutes of Health (NIH)-funded study has shown that Remdesivir has a clinical benefit i.e. reducing recovery times down to 11 days compared to 15 days. This NIH study did not show any mortality benefit. The UK based RECOVERY trial has also suggested the mortality benefit of using Dexamethasone in COVID-19 patients who need oxygen or are mechanically ventilated. However, the interim results of the WHO SOLIDARITY Trial( have shown “little or no effect on the 28 day mortality” of using remdesivir, hydroxychloroquine, lopinavi/ritonavir or interferons. Studies using repurposed medicines still continue to be conducted. It would appear that Remdesivir, being an antiviral, should be administered very early on in Covid-19 but we may not be seeing our patients during this early phase of their symptoms.Use of Dexamethasone is recommended and will be made available for the treatment of COVID-19. Remdesivir will also be added to our Specialist essential medicines list (EML -S list) and should be used in a hospital setting for those who are oxygen dependent. Dexamethasone is already available in our EMLen_ZW
dc.description.sponsorshipMinistry of Health & Child Care Republic of Zimbabween_ZW
dc.publisherMinistry of Health and Child Care: The National Medicine and Therapeutics Policy Advisory Committeeen_ZW
dc.subjectManagement of Covid-19en_ZW
dc.subjectCOVID-19 case management guidelinesen_ZW
dc.subjectManagement of Hospitalised Covid-19 patientsen_ZW
dc.subjectTherapeutic agents for COVID-19en_ZW
dc.titleZimbabwe Guidelines for the Management of Covid-19en_ZW
dc.typeTechnical Reporten_ZW

Files in this item


This item appears in the following Collection(s)

Show simple item record